Rosen P P, Menendez-Botet C J, Nisselbaum J S, Urban J A, Miké V, Fracchia A, Schwartz M K
Cancer Res. 1975 Nov;35(11 Pt 1):3187-94.
This report provides a detailed pathological review of 333 specimens analyzed for estrogen receptor protein (ERP) and correlates a series of morphological features with ERP results. Included were 147 primary breast carcinomas, 78 metastases, 27 fibroadenomas, and 81 nonneoplastic tissues, all from women. ERP in cytosols was assayed by incubation with [3H]estradiol in the presence and absence of "cold" estradiol followed by dextran-charcoal treatment. Results were summarized as positive (greater 60% inhibition by nontritiated estradiol, greater than 10 fmoles/mg protein), negative (less than 60% inhibition by nontritiated estradiol, less than 10 fmoles/mg protein), or intermediate borderline combinations. ERP in primary tumors ranged from 0.2 to 358 fmoles/mg protein (54.4% positive, 35.4% negative, 10.2% borderline). New findings are: (a) a high frequency of positive ERP in invasive lobular carcinoma (12 of 13, 92.3%) compared to typical ductal tumors (64 of 117, 54.7%); and (b) low frequency of positive ERP(5 of 21, 23.8%) in tumors with a prominent local lymphocyte reaction. Three ERP-positive noncarcinomatous specimens were fibroadenomas of high epithelial cellularity from patients under 30 years. No statistically significant relationship existed between ERP and any other morphological features that were examined.
本报告对333份分析雌激素受体蛋白（ERP）的标本进行了详细的病理学回顾，并将一系列形态学特征与ERP结果相关联。其中包括147例原发性乳腺癌、78例转移瘤、27例纤维腺瘤和81例非肿瘤组织，均来自女性。通过在有和没有“冷”雌二醇存在的情况下与[3H]雌二醇孵育，然后进行葡聚糖-活性炭处理来测定胞质溶胶中的ERP。结果总结为阳性（非氚化雌二醇抑制率大于60%，大于10飞摩尔/毫克蛋白）、阴性（非氚化雌二醇抑制率小于60%，小于10飞摩尔/毫克蛋白）或中间临界组合。原发性肿瘤中的ERP范围为0.2至358飞摩尔/毫克蛋白（54.4%为阳性，35.4%为阴性，10.2%为临界）。新发现有：（a）与典型导管肿瘤（117例中的64例，54.7%）相比，浸润性小叶癌中ERP阳性的频率较高（13例中的12例，92.3%）；（b）在有明显局部淋巴细胞反应的肿瘤中，ERP阳性的频率较低（21例中的5例，23.8%）。三个ERP阳性的非癌标本是30岁以下患者的高上皮细胞性纤维腺瘤。在所检查的任何其他形态学特征与ERP之间不存在统计学上的显著关系。
